Brief: GBS Inc Announces Application For FDA Breakthrough Device Designation To Fast Track Rapid Saliva Glucose Test
13/12/2021 13:23
Dec 13 (Reuters) - Gbs Inc GBS.O :
* GBS INC. ANNOUNCES APPLICATION FOR FDA BREAKTHROUGH DEVICE
DESIGNATION TO FAST TRACK RAPID SALIVA GLUCOSE TEST
Source text for Eikon: ID:nGNXtpghT
Further company coverage: GBS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study